We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Ablynx Initiates Phase I Study With ALX-0171 for the Treatment of Respiratory Syncytial Virus (RSV)


Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Ablynx Initiates Phase I Study With ALX-0171 for the Treatment of Respiratory Syncytial Virus (RSV) "

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:
 

The Phase I study is a single-centre, randomised, placebo-controlled trial that will investigate the safety, tolerability and PK profile of ALX-0171 in healthy volunteers. The study will include a single ascending dose part with six dose levels, which is expected to recruit 44 subjects, followed by a multiple dose part that is expected to recruit 16 subjects. Results of the study are anticipated during the second half of 2012.

Dr Edwin Moses, CEO and Chairman at Ablynx, commented: "We believe there is a high unmet need for a therapeutic treatment of RSV infection. ALX-0171 is the first Nanobody to enter clinical development that is administered through inhalation rather than injection. It has the potential to become a first-in- class therapeutic for RSV infections. This alternative route of administration in an acute disease setting is a good example of the competitive differentiation and advantages our Nanobody technology platform can bring. We are looking forward to seeing the results of this first-in-man trial, which are expected during the third quarter of 2012."

Advertisement